Multiple myeloma in China

Three BCMA-targeted CAR-T products are NMPA-approved in China for relapsed or refractory myeloma after at least three prior lines: equecabtagene (Fucaso), zevorcabtagene and ciltacabtagene (Carvykti). Only cilta-cel is also FDA-approved. Access is through hospital hematology departments or clinical trials.
VerifiedLast verified

Treatments available

TreatmentsStatus in ChinaStatus in USSources
Ciltacabtagene autoleucel (Carvykti), BCMA CAR-TApproved in ChinaApproved in ChinaPubMed Central
Equecabtagene autoleucel (Fucaso), BCMA CAR-TApproved in ChinaNot approvedNMPA (English)PubMed Central
Zevorcabtagene autoleucel, BCMA CAR-TApproved in ChinaNot approvedNMPA (English)PubMed Central
Autologous stem cell transplantAvailableApproved in China

Hospitals with documented programs

Informational listings from cited public sources, not recommendations.

Aerial view of Jiangsu Province Hospital (江苏省人民医院) campus on Guangzhou Road, Nanjing
NanjingJiangsu Province Hospital (First Affiliated Hospital of Nanjing Medical University)江苏省人民医院No public intl deptReported
Nanjing Drum Tower Hospital (南京鼓楼医院) building exterior
NanjingNanjing Drum Tower Hospital南京鼓楼医院No public intl deptReported
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (上海交通大学医学院附属瑞金医院) building exterior
ShanghaiRuijin Hospital, Shanghai Jiao Tong University School of Medicine上海交通大学医学院附属瑞金医院International deptVerified

Clinical trials

166studies listed as recruiting with a site in China on ClinicalTrials.gov, as of 2026-10-26. See the list

We link trials only; enrollment decisions belong to trial teams. Since May 2026, charging patients to join clinical research is prohibited in China, as reported by AFP.

Frequently asked

Which CAR-T products for myeloma are approved in China?

Equecabtagene (June 2023), zevorcabtagene (February 2024) and ciltacabtagene (Carvykti). All are for adults with relapsed or refractory disease after at least three prior lines including a proteasome inhibitor and an immunomodulatory agent.

[1] PubMed Central[2] NMPA (English)

Which Nanjing hospitals treat myeloma?

Jiangsu Province Hospital (hematology subspecialties), Nanjing Drum Tower Hospital and Jiangsu Cancer Hospital all run relevant programs; listings here are informational, not a recommendation.

[1] Xinhua Daily / Jiaoh…

Are there myeloma trials recruiting in China?

Yes. ClinicalTrials.gov listed 166 recruiting studies with a China site for multiple myeloma on 2026-10-26. Eligibility is set by each trial.

[1] ClinicalTrials.gov (…

Sources

  1. Ciltacabtagene Autoleucel Injection Approved for Marketing by China NMPA
    NMPA (English) · official · accessed 2026-10-26
    “It is indicated for the treatment of adults with relapsed or refractory multiple myeloma after three or more prior lines of therapy and progressed, including a proteasome inhibitor and an immunomodulatory agent.”
  2. Redefining CAR-T regulation: China's responses to address secondary cancer risks of CAR-T therapy (Table 1)
    PubMed Central · official · accessed 2026-10-26
    “Table 1 lists zevor-cel (NMPA, 2024-02-23), inati-cel (NMPA, 2023-11-07) and eque-cel/Fucaso (NMPA, 2023-06-30).”
  3. 16 CAR-T Therapies and Counting
    BioInformant · news · accessed 2026-10-26
    “Seven therapies have been approved by the U.S. FDA.”
  4. Foreign patients coming to China for care (Jiangsu)
    Xinhua Daily / Jiaohuidian · news · accessed 2026-10-26
  5. China lures foreign patients with cutting-edge, cheap medical care
    AFP / Free Malaysia Today · news · accessed 2026-10-26

Information only. Not medical advice, diagnosis or a treatment recommendation. Talk to your doctor. In an emergency, call your local emergency number.